Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: L01FX08

Empliciti(Elotuzumab)

Multiple Myeloma

Marketing Authorisation Holder: Bristol-Myers Squibb Pharma EEIG

EMA Authorisation: 11/05/2016

INN: elotuzumab

Indication

Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see sections 4.2 and 5.1).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Empliciti — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.